On July 25, 2002, Nichols, David Earl; Mailman, Richard Bernard; Huang, Xuemei published a patent.SDS of cas: 58142-46-4 The title of the patent was Method using D1 dopamine receptor agonists for treatment of dopamine-related dysfunction. And the patent contained the following:
The invention relates to the treatment of dopamine-related dysfunction using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “”off-period””. The D1 agonist concentration is reduced during the “”off-period”” to obtain a plasma concentration of agonist that suboptimally activates D1 dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises administering to a patient a full D1 agonist with a half-life of up to about 6 h periodically at a dose resulting in a first plasma concentration of agonist capable of activating D1 dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 h to obtain a second lower plasma concentration of agonist which results in suboptimal activation of D1 dopamine receptors for a period of time sufficient to prevent induction of tolerance. The dopamine D1 agonist is e.g. dinoxyline (preparation described). The methodol. of the invention may be used to treat e.g. Parkinson’s disease. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).SDS of cas: 58142-46-4
The Article related to dopamine related disease treatment d1 agonist tolerance prevention, dinoxyline preparation d1 agonist dopamine disease treatment, parkinson disease dopamine d1 agonist tolerance prevention and other aspects.SDS of cas: 58142-46-4
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem